Scarica l'app Stockscreener
0.8631
5.26%
0.0431
Dopo l'orario di chiusura:
.86
-0.0031
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Will Iterum Therapeutics plc continue its uptrendJuly 2025 Breakouts & Weekly Watchlist of Top Performers - Newser
Iterum Therapeutics plc stock trend outlook and recovery path2025 Pullback Review & Stock Portfolio Risk Management - Newser
Is Iterum Therapeutics plc reversing from oversold territoryMarket Activity Report & Reliable Volume Spike Alerts - Newser
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call Transcript - MSN
Using Bollinger Bands to evaluate Iterum Therapeutics plcWeekly Risk Summary & Capital Efficient Trading Techniques - Newser
Using data filters to optimize entry into Iterum Therapeutics plc2025 Top Decliners & Safe Capital Growth Tips - Newser
ITRM Reports Results - AOL.com
Analyzing Iterum Therapeutics plc with multi timeframe chartsGap Down & Weekly Top Performers Watchlists - Newser
Chart based exit strategy for Iterum Therapeutics plc2025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - Newser
Price momentum metrics for Iterum Therapeutics plc explainedJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser
What’s next for Iterum Therapeutics plc stock priceLow Risk Stock Trade Opportunity Analysis - Newser
What institutional flow reveals about Iterum Therapeutics plcPattern Recognition Based Market Move Prediction - Newser
Using economic indicators to assess Iterum Therapeutics plc potentialStock Market Watch with Smart Filters - Newser
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcSmart Trend Analysis With Buy Point Cues - Newser
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares By Investing.com - Investing.com Australia
Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8. - AInvest
Real time pattern detection on Iterum Therapeutics plc stockSecure Buy Strategy Based on Risk Parameters - Newser
Why Iterum Therapeutics plc stock attracts strong analyst attentionLow Drawdown Picks with Weekly Updates - Newser
Developing predictive dashboards with Iterum Therapeutics plc dataFuture Growth Stock Forecasting Strategy - Newser
Will Iterum Therapeutics plc stock recover after recent dropReal Stock Picks With Setup Verification - Newser
Iterum Therapeutics (NASDAQ:ITRM) Downgraded by Wall Street Zen to “Sell” - Defense World
Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Up 54.6% in July - Defense World
ITRM Reports Results - The Motley Fool
Iterum Therapeutics PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Iterum Therapeutics (ITRM) Financial Outlook for 2025 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics reports Q2 results, launches ORLYNVAH, extends cash runway to 2026. - AInvest
Iterum Therapeutics to Launch ORLYNVAH™ for Uncomplicated UTIs in August 2025, Reports Q2 Financial Results - Quiver Quantitative
Iterum Therapeutics Reports Second Quarter 2025 Financial Results - The Manila Times
Iterum Therapeutics reports Q2 revenue, cash runway into 2026, ORLYNVAH launch in August. - AInvest
Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch - Stock Titan
Iterum Therapeutics (NASDAQ:ITRM) Shares Down 2.5% – Here’s Why - Defense World
Iterum Therapeutics Q2 Earnings Preview: Analysts Expect EPS of $-0.13 - AInvest
How to forecast Iterum Therapeutics plc trends using time seriesBull Market Summary and Recovery Outlook - Newser
What makes Iterum Therapeutics plc stock price move sharplyFree Accurate Technical Trend Reversal Picks - Newser
Exit strategy if you’re trapped in Iterum Therapeutics plcWealth Accumulation Outlook for Safe Investors - Newser
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):